Can B Corp (NASC) stock
NASCOTCWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends December 31
Financials through Q3 FY2024, quarter ended Sep 30, 2024Last filing: 10-Q on Nov 19, 2024
$0.01−0.00 (-1.32%)
Close on Oct 19, 2026Market cap $981.54KP/E –Yield –
Can B r&d expenses
Research and development expenses are spending on new products and technology.
Can B's R&D Expenses for the twelve months ending Dec 31, 2020 was $165.00K, up 10.0% year over year. For fiscal 2020 it was $165.00K, up 10.0% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $165.00K | +10.0% |
| FY2019 | Dec 31, 2019 | $150.00K | +100.0% |
| FY2018 | Dec 31, 2018 | $75.00K | +102.7% |
| FY2017 | Dec 31, 2017 | $37.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2020 | Dec 31, 2020 | $85.00K | -19.0% |
| Q3 FY2020 | Sep 30, 2020 | $55.00K | +57.1% |
| Q2 FY2020 | Jun 30, 2020 | $0 | -100.0% |
| Q1 FY2020 | Mar 31, 2020 | $25.00K | +42.9% |
| Q4 FY2019 | Dec 31, 2019 | $105.00K | +68.0% |
| Q3 FY2019 | Sep 30, 2019 | $35.00K | – |
| Q2 FY2019 | Jun 30, 2019 | $52.50K | +425.0% |
| Q1 FY2019 | Mar 31, 2019 | $17.50K | +600.0% |
| Q4 FY2018 | Dec 31, 2018 | $62.50K | – |
| Q3 FY2018 | Sep 30, 2018 | $0 | – |
| Q2 FY2018 | Jun 30, 2018 | $10.00K | – |
| Q1 FY2018 | Mar 31, 2018 | $2.50K | – |
See a number that looks wrong?